The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors - Takeaways - MDSpire

The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors

  • By

  • Haixia Yang

  • Yaxuan Han

  • Xiaosha Zhou

  • Jianying Li

  • Yanjun Zhao

  • Shanshan Zhang

  • December 15, 2025

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICIs) enhance immune response in lung cancer but can lead to immune-related adverse events, including pneumonitis.

  • 2

    Pulmonary infections are common in lung cancer patients treated with ICIs, with infection rates reported between 18% and 27% in various studies.

  • 3

    Diabetes mellitus is identified as a significant risk factor for developing infections in lung cancer patients undergoing ICI therapy.

  • 4

    The study aims to systematically investigate the incidence and risk factors of pulmonary infections specifically in ICI-treated lung cancer patients.

  • 5

    Current evidence on post-ICI infections is primarily from retrospective analyses, highlighting the need for more focused research on infection epidemiology.

Original Source(s)

The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors

  • by Haixia Yang, Yaxuan Han, Xiaosha Zhou, Jianying Li, Yanjun Zhao, Shanshan Zhang

  • December 15, 2025

Related Content

Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription

Case report and literature review: the effect of surgical management in intrathoracic pseudomyxoma peritonei

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method